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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (SCT)
is an important therapy for a number of malignant and non-
malignant disorders. Unfortunately, the utility of allogeneic
SCT is limited by a number of side effects, the 2 most fre-
quent of which are graft-versus-host disease (GVHD) and
pulmonary toxicity. Pulmonary dysfunction of various forms
occurs in up to 55% of transplant recipients and can account
for as much as 50% of SCT-related mortality [1-6]. Approxi-
mately half of the lung insults that occur in this setting are
noninfectious in origin and are referred to as idiopathic
pneumonia syndrome (IPS) when they occur within the ﬁrst
100 days of SCT [7]. Perhaps the most striking feature of IPS
is its impact on overall survival; mortality rates of 50% to
70% have been reported [2,6,7], and the clinical response to
standard therapeutic approaches including high-dose steroids
and broad-spectrum antibiotics is limited.
In a retrospective analysis of 425 allogeneic hemato-
poietic SCTs (193 unrelated donor [URD] bone marrow
and 232 related donor peripheral blood stem cell [PBSC])
performed at the University of Michigan between June 1995
and February 2000, 35% of the URD transplant recipients
and 22% of the related donor PBSC transplant recipients
developed lung dysfunction within 100 days of bone marrow
transplantation (BMT). The incidence of IPS after allo-
geneic SCT ranged from 5% to 20%, depending on the
donor source and the degree of antigenic mismatch between
donor and host. All patients were treated with steroids and
broad-spectrum antibiotics. The median times to onset of
IPS were 13 and 18 days after URD and related PBSC
transplantation, respectively. In 19 (60%) of 32 patients, the
onset of respiratory symptoms occurred within 7 days of
engraftment (absolute neutrophil count >500). IPS was
associated with acute GVHD in 72% of cases and hepatic
veno-occlusive disease (VOD) preceded the onset of IPS in
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11 (34%) of 32 cases. Strikingly, the overall day 100 mortal-
ity for patients with IPS was 94% (30 of 32) and the median
time to death from onset of IPS was 13 days.
During this same time period, our laboratory and others
used mouse SCT models to examine the immunologic
mechanisms responsible for IPS. Preclinical data demon-
strate that tumor necrosis factor α (TNFα) is a signiﬁcant
contributor to lung injury and that donor-derived, alloreac-
tive T-cells are also associated with this process [8-15].
Based on these laboratory ﬁndings, and in light of the poor
clinical response to standard therapy, we administered etan-
ercept (Enbrel; Immunex, Seattle, WA), a US Food and
Drug Administration–approved TNFα-neutralizing agent,
to 3 consecutive patients who developed IPS after allogeneic
SCT. In each case, etanercept therapy was well tolerated and
was associated with signiﬁcant improvement of pulmonary
dysfunction within the ﬁrst week of treatment.
STUDY POPULATION
Three consecutive pediatric patients who received allo-
geneic SCT and developed IPS at the University of Michi-
gan between August and December 2000 are included in this
report. Conditioning regimens included cyclophosphamide/
fludarabine (patient 1), cyclophosphamide/busulfan
(patient 2) and cyclophosphamide/busulfan/cytosine arabi-
noside (patient 3) as described [16-18]. Patient characteris-
tics along with BMT conditioning and GVHD prophylaxis
regimens are summarized in Table 1. All data were
retrieved from information prospectively collected at the
time of SCT. The results of all bronchoscopies, biopsies,
and autopsies were reviewed. Infectious prophylaxis
included sulfamethoxazole and trimethoprim, fluconazole,
norfloxacin, and acyclovir. Granulocyte colony-stimulating
factor (Neupogen; Amgen, Thousand Oaks, CA) was
administered to all patients posttransplantation. Each
patient’s condition fulfilled criteria for IPS, as determined
by the following: diffuse multilobar infiltrates visible on
radiographic examination (chest x-ray or computed tomo-
graphic scans), signs and symptoms of pneumonia (cough,
dyspnea, rales), and evidence of abnormal respiratory phys-
iology based on (1) increased alveolar-arterial oxygen gradi-
ent, (2) requirement of supplemental oxygen to maintain
an oxygen saturation >93%, or (3) PaO2/FiO2 ≤ 300. Fur-
thermore, absence of active lower respiratory tract infec-
tion in each patient was confirmed by results of the follow-
ing tests on bronchoalveolar lavage (BAL) fluid: gram
stain; quantitative bacterial culture; viral culture for respi-
ratory syncytial virus, parainfluenza, adenovirus, influenza
A and B, herpes simplex virus, and cytomegalovirus
(CMV); shell-vial CMV culture; fungal and mycobacterial
cultures; stains for fungi, acid-fast bacilli and Pneumocystis
carinii pneumonia (PCP); and polymerase chain reaction
(PCR) for PCP. Test results from BAL ﬂuid and serum sam-
ples from each patient were negative for infectious organ-
isms for at least 24 to 36 hours prior to the start of etaner-
cept therapy. No patient had signs or symptoms of fluid
overload or left heart failure (as determined by physical
exam and the lack of response to diuretic therapy) as the
cause of respiratory distress.
Etanercept, a dimeric protein consisting of 2 soluble
p75 TNF receptors fused to the Fc portion of a type I
immunoglobulin (IgG1) molecule, was reconstituted from a
lyophilized powder and administered subcutaneously at a
dose of 0.4 mg/kg (maximum dose, 25 mg) twice weekly
(with 72 to 96 hours between doses) for a maximum total of
8 doses. Therapy was discontinued and not reinstituted if
one of the following criteria were subsequently met: (1) cul-
tures, special stains, or PCR results of BAL ﬂuid, blood, or
biopsy specimens became positive for a potentially infec-
tious organism; (2) the patient developed signs and symp-
toms consistent with the diagnosis of sepsis syndrome; or (3)
the patient became seropositive for the pp65 antigen and
was believed to have active CMV disease.
RESULTS
Three consecutive allogeneic hematopoietic SCT recip-
ients with acute pulmonary dysfunction were treated with
etanercept at the University of Michigan Stem Cell Trans-
plant Program. All 3 patients were younger than 18 years
and experienced pulmonary dysfunction that met the clinical
Table 1. Characteristics of Patients Receiving Etanercept for Idiopathic Pneumonia Syndrome (IPS)*
Patient 1 Patient 2 Patient 3
Age, y 14 15 15
Sex Male Male Male
Diagnosis Renal cell carcinoma Relapsed AML Relapsed AML
Disease status Progressive disease Second remission Second remission
Donor Maternal Sibling Unrelated
HLA match 4 of 6 5 of 6 6 of 6
SCT prep Cy + Fludar Cy + Bu Cy + Bu + AraC
GVHD prophylaxis CSA + MTX + ATG Tacro + MTX Tacro + MTX
Prior radiation therapy None None None
Engraftment Day +8 Day +13 Day +16
Onset of IPS Day +8 Day +13 Day +57
GVHD Present Yes No No
VOD Present No Yes Yes
*Cy indicates cyclophosphamide; Fludar, ﬂudarabine; Bu, busulfan; AraC, cytosine arabinoside; CSA, cyclosporin A; MTX, methotrexate; ATG,
antithymocyte globulin; Tacro, tacrolimus.
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criteria for IPS (as described above) at the time of etaner-
cept therapy. Each patient received empiric broad-spectrum
antibacterial and antifungal therapy and methylprednisolone
(2 mg/kg per day) prior to and during the administration of
etanercept. However, antiinﬂammatory agents such COX-2
inhibitors or other interventions for acute lung injury were
not used in any patient. In each case, etanercept therapy was
well tolerated, with no reported infusion-related reactions,
and was associated with significant improvement in pul-
monary dysfunction after 1 to 2 doses. Brief synopses follow
of each patient’s clinical course and radiographic changes.
Patient 1
Patient 1, a 14-year-old boy, underwent a non–T-cell–
depleted 2-antigen mismatched maternal donor PBSC
transplantation for progressive renal cell carcinoma (multi-
focal bone, pulmonary, and abdominal disease). The patient
developed signs and symptoms of acute pulmonary dysfunc-
tion on day +8 after transplantation, along with the concur-
rent development of acute GVHD of the liver and skin
(biopsy proven). Methylprednisolone, antithymocyte globu-
lin, amphotericin, and broad-spectrum antibiotic therapy
were administered. By day +10, the patient progressed to
grade III acute GVHD with diffuse bilateral pulmonary
infiltrates (Figure 1A). The patient underwent bron-
choscopy, and etanercept therapy was initiated 36 hours
after BAL ﬂuid analysis results were found to be negative for
all pathogens tested. The patient received 8 doses of etaner-
cept administered over a 4-week period. Within the first
7 days of etanercept therapy, the patient was weaned from
100% oxygen via a bilevel positive airway pressure (BiPAP)
mask to room air with complete resolution of his pulmonary
inﬁltrates (Figure 1B), and his systemic GVHD improved to
grade I. The patient was subsequently discharged from the
Figure 1. Chest radiographs obtained on day 0 (A) and day 4 (B) of therapy with etanercept for patient 1.
Figure 2. Chest radiographs obtained on day 0 (A) and day 7 (B) of therapy with etanercept for patient 2.
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hospital without signs or symptoms of respiratory dysfunction.
The patient later died of progressive renal cell carcinoma 119
days after SCT.
Patient 2
Patient 2, a 15-year-old boy, underwent a 1-antigen–
mismatched related donor PBSC transplantation for acute
myeloid leukemia (AML) in second complete remission
(CR2). The patient developed diffuse bilateral lung disease
on SCT day +13 (Figure 2A) in association with severe
hepatic VOD (total bilirubin >10 mg/dL). Etanercept therapy
was initiated on day +16, 36 hours following intubation and
bronchoscopy. BAL fluid results were negative for all
pathogens tested. Two doses of etanercept were administered
96 hours apart. Significant improvement in ventilatory
parameters (Table 2) and radiographic abnormalities (Figure
2B) were noted within 7 days following etanercept administra-
tion. The patient was extubated and discharged from the
intensive care unit. The patient subsequently developed gram-
positive bacteremia and CMV reactivation, each of which
were successfully treated. The patient’s hepatic VOD and
dysfunction persisted and he ultimately died of progressive
hepatic failure on day +89 of SCT.
Patient 3
Patient 3, a 15-year-old boy, received a URD marrow
transplant for the treatment of AML in CR2. On SCT day
+55, the patient developed diffuse bilateral inﬁltrates visible
on chest x-ray (Figure 3A) and signiﬁcant pulmonary dys-
function in association with severe VOD (total bilirubin,
39 mg/dL, biopsy proven). By day +56, the patient required
endotracheal intubation and mechanical ventilation with
high ventilatory settings (Table 3). The patient began etaner-
cept therapy on day +57 posttransplantation after BAL ﬂuid
results were negative for infection. Within 24 hours of the
initial etanercept dose, the patient’s pulmonary dysfunction
improved, and by 48 hours, ventilator settings were signiﬁ-
cantly weaned (Table 3). The patient was extubated 6 days
after the initiation of therapy with signiﬁcant clearing of his
pulmonary infiltrates (Figure 3B). The patient received a
total of 4 doses of etanercept therapy and was later trans-
ferred back to the SCT unit. The patient’s subsequent course
included the development of progressive hepatic VOD, renal
failure, esophageal varices, and gram-positive bacteremia fol-
lowed by candidemia. Although both infections were success-
fully treated, the patient died on BMT day +110 of gastro-
intestinal bleeding secondary to severe hepatic injury, which
was conﬁrmed on postmortem exam.
DISCUSSION
Acute pulmonary dysfunction remains a frequent and
severe complication of allogeneic hematopoietic SCT, and
almost half of the pneumonias that occur in this setting are
noninfectious in origin [7]. In 1993, a panel convened by the
National Institutes of Health proposed a broad working def-
inition of IPS to include widespread alveolar injury in the
absence of active lower respiratory tract infection following
BMT [7]. Diagnostic criteria of IPS include signs and symp-
toms of pneumonia, evidence for nonlobar radiographic
infiltrates and abnormal pulmonary function, and the
absence of infectious organisms in the lower respiratory
tract [2,7]. A variety of histopathologic ﬁndings have been
associated with IPS; however, the most frequently reported
pattern is interstitial pneumonitis, a term that historically
has often been used for IPS. The time of onset for IPS
Table 2. Clinical Response of Patient 2 to Etanercept Administration*
Day after Etanercept Therapy
Day 0 Day 1 Day 3 Day 7
FiO2, % 55 45 40 30
PIP/PEEP 29/10 26/8 22/5 22/5
MAP 14 14 8 7
*FiO2 indicates percent inspired oxygen; PIP, peak inspiratory pres-
sure; PEEP, peak end expiratory pressure; MAP, mean airway pressure.
Figure 3. Chest radiographs obtained on day 0 (A) and day 7 (B) of therapy with etanercept for patient 3.
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ranges from 14 to 90 days after infusion of the donor bone
marrow innoculum, and mortality rates of 50% to 70% have
been reported [2,3,5-7,19]. Although a recent retrospective
study from the Seattle group reported a lower incidence and
earlier onset of IPS than previously reported (median time
to onset, 21 versus 42-49 days), the typical clinical course
involving the rapid onset of respiratory failure leading to
death remained unchanged, underscoring the critical nature
of this transplantation-related problem [6].
Potential etiologies for IPS are several and include direct
toxic effects of SCT conditioning regimens, occult pul-
monary infections, and inflammatory cytokines that have
been implicated in other forms of pulmonary injury [20-24].
A role for inﬂammatory cytokines in the evolution of IPS is
supported by a number of clinical and experimental observa-
tions. Elevations of TNF have been reported in the serum
of patients who developed lung injury after SCT [25] and in
the lungs of animals with GVHD [8,12-14]. Furthermore,
neutralization of TNFα using the etanercept molecule after
BMT signiﬁcantly reduced the severity of experimental IPS
[10]. Evidence for cytokine activation and lipopolysaccharide
(LPS) amplification, which have been noted in the bron-
choalveolar compartment during adult respiratory distress
syndrome [26], has recently also been found in patients with
IPS after allogeneic SCT [1]. Clark and colleagues found
increased vascular permeability and BAL ﬂuid levels of inter-
leukin IL-1, IL-12, IL-6, TNFα and components of the LPS
ampliﬁcation system (LPB and CD14) in patients with IPS
[1]. The investigators concluded that proinflammatory
cytokine activation contributes to the pathogenesis of lung
injury posttransplantation and suggest that patients with this
complication may be at increased risk for LPS-mediated lung
injury. These ﬁndings are signiﬁcant because they support a
paradigm shift in the current understanding of acute lung
injury after SCT; rather than simply representing a clinical
syndrome, IPS may be a process in which the lung is directly
susceptible to immune-mediated injury.
In the current report, each recipient was at high risk for
transplantation-related complications including IPS;
2 patients received mismatched family member transplants
and 1 patient received a matched URD SCT. In each
patient, etanercept administration was associated with an
improvement in respiratory function, and no adverse drug
reactions were observed. In 2 patients, etanercept was dis-
continued after resolution of pulmonary dysfunction
because of evidence for systemic infection with either gram-
positive bacteria or Candida. Importantly, however, each
infection was successfully treated and neither patient died of
uncontrolled sepsis.
Etanercept has not been shown to increase the risk of
infection when administered to patients with rheumatoid
arthritis [27]. However, recipients of mismatched and URD
transplants are at very high risk for both bacterial and fungal
infections for a number of reasons, including the immuno-
ablative effects of SCT conditioning regimens, the need for
prolonged immunosuppression to prevent or treat GVHD,
and the increased risk of other SCT complications, includ-
ing acute GVHD, that can further impair host defense.
Because TNFα is now known to be important in the clear-
ance of bacterial and fungal infections [28-31], careful moni-
toring for infection in SCT patients receiving etanercept is
warranted. The administration of etanercept after SCT has
been reported in a small subset of patients with steroid-
dependent chronic GVHD, and it was well tolerated and
not associated with an increased risk of infection [32].
In conclusion, the combination of etanercept and
steroids for patients with IPS after allogeneic hemato-
poietic SCT was well tolerated and was associated with
significant clinical and radiographic improvement in all 3
patients treated. Although each patient in this series ulti-
mately died, the time from diagnosis of IPS to death in
the 3 patients was 111, 73, and 55 days, compared to the
median of 13 days in our historical controls. Importantly,
respiratory failure was not the primary cause of death in
any patient. These preliminary data suggest that TNFα
neutralization with etanercept may be an effective adjunct
to standard forms of immunosuppression used to treat
this form of pulmonary toxicity. However, the use of
etanercept for IPS should be tested in carefully moni-
tored clinical protocols designed to study the feasibility,
safety, and potential efficacy of this novel strategy. Phase
I/II clinical trials are currently open at the University of
Michigan to study this agent both in patients with IPS
and subacute noninfectious lung injury after allogeneic
hematopoietic SCT.
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